3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
27
Prostatic Neoplasms
5
Osteosarcoma
5
Neuroendocrine Tumors
5
Neoplasms
5
Colorectal Neoplasms
5
Clear-cell metastatic renal cell carcinoma
5
Carcinoma, Hepatocellular
5
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Sarcoma, Ewing
3
Sarcoma
3
Neoplasm Metastasis
3
Kidney Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Medullary
3
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Small Cell Lung Carcinoma
2
Penile Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma
2
Adrenocortical Carcinoma
2
von Hippel-Lindau Disease
1
Wilms Tumor
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
90 days
×
Clear all
No trials found.